Small Molecule Vascular Disrupting Agents to Hold Largest Market Share in 2020
According to Absolute Markets Insights report, Small molecules VDAs accounted for the largest share in the global vascular disrupting agents (VDAs) market in 2020. Small-molecule vascular disrupting agents target the established tumor blood vessels resulting in rapidly and selectively widespread ischemia and necrosis of central tumor. Hence, they have shown notable efficacy in treating various cancers such as sarcoma, prostate cancer, ovarian cancer, etc. Also, research initiatives are being directed to provide a treatment strategy that has more success rate for overall survival as they have the ability to target different mechanisms through which cancer develops and grow. These small molecule VDAs are in a more advanced stage of clinical development. For instance, DMXAA (5,6-dimethylxanthenone-4-acetic acid) is a typical small-molecule VDAs which is currently in clinical trial, is proven efficient to different tumor types as it selectively targets the tumor vascular endothelium, destroy the tumor vasculature, and cut off the tumor blood supply, leading to the ischemic necrosis of tumor cells. The phase III segment dominated the global vascular disrupting agents (VDAs) market as many of the vascular disrupting agent drugs have entered the phase III trials. For instance, Plinabulin drug indicated for small non-cell lung cancer is in phase III trial. Also, Icaritin drug is in phase III trial, which is indicated for hepatocellular carcinoma.
Get PDF sample report with all related graphs & charts (pre and post covid-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1071
The non-small cell lung cancer segment is the largest segment in the global vascular disrupting agents (VDAs) market and this dominance is attributed to the high incidence of lung cancer. Lung cancer is the deadliest cancer worldwide, accounting for 1.79 million deaths in 2020, and is the sixth leading cause of death worldwide. Several therapies targeting angiogenesis are currently in development for non-small cell lung cancer.
The combination therapy segment dominated the global vascular disrupting agents (VDAs) market in 2020. The therapy has proven efficient for treating the tumors. Some of the combination therapy includes VB-111, which is in phase III trial and is indicated for glioblastoma.
The intravenous segment accounted for the highest share in the global vascular disrupting agents (VDAs) market. Intravenous route of administration targets the specific cell or organ and eliminates the process of drug absorption and breakdown by directly depositing it into the blood.
North America accounted for a prominent share in the global vascular disrupting agents (VDAs) market owing to the increasing investments in the research and development by companies in the region. The increasing number of cancer patient pool in the region is fuelling the market growth. Also, the presence of key players in the region and government initiatives is anticipated to grow the market. Moreover, in U.S, almost 306 clinical studies are evaluating various types of vascular disrupting agent, which thereby positive growth prospects for the region’s growth in the future years.
Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1071
How Absolute Market Insights is unique in nature?
The research report on Vascular Disrupting Agents (VDAs) Market will include extensive information based on the following pointers:
- Global Market size and forecast values in terms of revenue (US$ Million) by segments/sub-segments
- Split of the market revenue (US$ Million) into all the relevant segments & sub-segments across all major regions/countries.
- Market Determinants and Influencing Factors
- Macro-Economic and Micro-Economic Indicators
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Trends on Global Vascular Disrupting Agents (VDAs) Market
- Exclusive Details on the Effect of the Pandemic
- Porter’s Five Forces Analysis
- Competitor Landscape
- Product Benchmarking
- Market Share Analysis, 2020
- Global Presence and Growth Strategies
- The final report will include competitive product benchmarking which will encompass comparison of varied services offered by different market participants on the basis of their features and capabilities that will help you to understand their market offerings. Furthermore, for each company, we will provide information regarding company details, company overview, product offerings, key developments, financial analysis, and SWOT analysis and business strategies.
- The research study specific to a region, including North America, Europe, Asia Pacific, Middle East & Africa and Latin America, is also available.
- We offer our reports in different languages which include German, Chinese, French, Russian, Spanish, Arabic, Japanese and Korean amongst others.
View our other exclusive press releases on: https://industryglobalnews24.com/categories/press-release
Key Findings:
- Small molecule VDAs segment registered for the major share of revenue in the vascular disrupting agent market in 2020.
- By development phase, phase III segment accounted for the highest market share in the global vascular disrupting agents (VDAs) market in 2020. Substantial funding being directed for drugs in this stage of development has triggered the highest share for the segment.
- By therapeutic indication, non-small cell lung cancer dominated the market in the vascular disrupting agent market in 2020. Increased prevalence of the disease has contributed towards the segment’s largest share in the global vascular disrupting agents (VDAs) market.
- Combination therapy in the global vascular disrupting agents (VDAs) market accounted for the major share in 2020 owing to the highest rate for positive outcome from the same. The segment is anticipated to further accelerate with increasing investments into research and development activities in the sector.
- Asia Pacific is anticipated to witness fastest growth rate in the global vascular disrupting agents (VDAs) market over the period of next eight years. Increasing investments towards development in the healthcare sector is primarily contributing towards the region’s growth.
Competitor Insights:
The key companies profiled in the global vascular disrupting agents (VDAs) market are mentioned below:
- Bionomics
- Iceni Pharmaceuticals
- MediciNova, Inc.
- Oncotelic Inc., a TGF ImmunoOncology Company
- Vascular Biogenics
- Other Market Participants
The industry is characterized by a high concentration of market players, especially by region. A high degree of integration across the supply chain is witnessed among these players. Furthermore, market participants in the industry are focused on collaborations with end-users to improve their product line in conjunction with the circular economy.
Purchase the latest in-depth report: https://www.absolutemarketsinsights.com/checkout?id=1071
Global Vascular Disrupting Agents (VDAs) Market:
By Type:
- Small molecule VDAs
- Tubulin – binding agents
- Flavonoids
- Ligand Directed VDAs
By Development Phase:
- Preclinical phase
- Phase I
- Phase II
- Phase III
By Therapeutic Indication:
- Melanoma
- Non-Small Cell Lung Cancer
- Prostate Cancer
- Renal and Ovarian Cancer
- Glioblastoma
- Others
By Therapy Type:
- Mono Therapy
- Combination Type
By Route of Administration
- Intravenous
- Oral
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Browse more trending reports by Absolute Markets Insights:
Global Novel Drug Delivery Systems Market - Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 – 2029
Hospital EMR Systems Market - Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 – 2029
Global Non-Alcoholic Steatohepatitis Biomarkers Market - Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 – 2029
ENT Chairs Market – Global Insights, Growth, Size, Comparative Analysis, Trends And Forecast, 2021 - 2029
Global HealthTech Market will grow to US$ 456.85 Mn by 2028 at 19% CAGR- says Absolute Markets Insights
Global Identity Theft Protection Services Market is Expected to Reach US$ 8522.07 Million by 2027, Growing at an Estimated CAGR of 5.8% Over the Forecast Period due to Increasing Digital Payments and E-commerce Transactions
Glance through Absolute Markets Insights plethora of reports on: https://www.absolutemarketsinsights.com/categories/healthcare
Contact Us:
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-740-024-2424 , US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com/